Squarepoint’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-121,477
| Closed | -$5.77M | – | 4210 |
|
|
2025
Q3 | $5.77M | Buy |
121,477
+96,030
| +377% | +$4.65M | 0.01% | 1374 |
|
|
2025
Q2 | $1.36M | Sell |
25,447
-15,214
| -37% | -$691K | ﹤0.01% | 2395 |
|
|
2025
Q1 | $1.65M | Buy |
+40,661
| New | +$1.72M | ﹤0.01% | 2253 |
|
|
2024
Q2 | – | Sell |
-7,997
| Closed | -$202K | – | 4002 |
|
|
2024
Q1 | $202K | Sell |
7,997
-67,152
| -89% | -$1.61M | ﹤0.01% | 3615 |
|
|
2023
Q4 | $1.75M | Buy |
75,149
+39,558
| +111% | +$780K | ﹤0.01% | 2095 |
|
|
2023
Q3 | $1.8M | Buy |
+35,591
| New | +$1.66M | ﹤0.01% | 1899 |
|
|
2023
Q2 | – | Sell |
-20,091
| Closed | -$769K | – | 3520 |
|
|
2023
Q1 | $769K | Sell |
20,091
-6,945
| -26% | -$310K | ﹤0.01% | 2061 |
|
|
2022
Q4 | $1.48M | Buy |
+27,036
| New | +$1.16M | 0.01% | 1552 |
|
|
2021
Q1 | – | Sell |
-39,815
| Closed | -$1.03M | – | 3054 |
|
|
2020
Q4 | $1.03M | Buy |
39,815
+29,830
| +299% | +$830K | 0.01% | 1310 |
|
|
2020
Q3 | $307K | Sell |
9,985
-5,103
| -34% | -$178K | ﹤0.01% | 1777 |
|
|
2020
Q2 | $376K | Sell |
15,088
-4,310
| -22% | -$98.5K | 0.01% | 1467 |
|
|
2020
Q1 | $411K | Sell |
19,398
-39,110
| -67% | -$839K | 0.01% | 1141 |
|
|
2019
Q4 | $1.3M | Buy |
58,508
+39,634
| +210% | +$820K | 0.01% | 1175 |
|
|
2019
Q3 | $429K | Buy |
+18,874
| New | +$439K | ﹤0.01% | 1698 |
|
Other funds holding AKRO
Squarepoint's AKRO Position: Q4 2025 in Review
Squarepoint sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 121,477 shares — an estimated $5.77M sold.
Squarepoint first reported a position in AKRO in Q3 2019 and held it in 14 quarters. The position peaked at $5.77M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Squarepoint reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Squarepoint sold 121,477 Akero Therapeutics shares in Q4 2025, an estimated $5.77M.
- Squarepoint first reported a position in Akero Therapeutics in Q3 2019 and held it in 14 quarters.
- Squarepoint's Akero Therapeutics position peaked at $5.77M in Q3 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Squarepoint's 13F filing for Q4 2025, filed 13 Feb 2026.